PL2737081T3 - Sposób przewidywania odpowiedzi na chemioterapię u pacjenta cierpiącego na lub u którego występuje ryzyko wystąpienia nawrotu raka sutka - Google Patents

Sposób przewidywania odpowiedzi na chemioterapię u pacjenta cierpiącego na lub u którego występuje ryzyko wystąpienia nawrotu raka sutka

Info

Publication number
PL2737081T3
PL2737081T3 PL12740974T PL12740974T PL2737081T3 PL 2737081 T3 PL2737081 T3 PL 2737081T3 PL 12740974 T PL12740974 T PL 12740974T PL 12740974 T PL12740974 T PL 12740974T PL 2737081 T3 PL2737081 T3 PL 2737081T3
Authority
PL
Poland
Prior art keywords
chemotherapy
patient
risk
breast cancer
cancer recurrence
Prior art date
Application number
PL12740974T
Other languages
English (en)
Inventor
Mathias Gehrmann
Karsten Weber
Ralf Kronenwett
Christoph Petry
Jan Brase
Original Assignee
Sividon Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sividon Diagnostics Gmbh filed Critical Sividon Diagnostics Gmbh
Publication of PL2737081T3 publication Critical patent/PL2737081T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL12740974T 2011-07-28 2012-07-30 Sposób przewidywania odpowiedzi na chemioterapię u pacjenta cierpiącego na lub u którego występuje ryzyko wystąpienia nawrotu raka sutka PL2737081T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11175852 2011-07-28
EP12740974.6A EP2737081B1 (en) 2011-07-28 2012-07-30 Method for predicting the response to chemotherapy in a patient suffering from or at risk of developing recurrent breast cancer

Publications (1)

Publication Number Publication Date
PL2737081T3 true PL2737081T3 (pl) 2017-04-28

Family

ID=46598521

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12740974T PL2737081T3 (pl) 2011-07-28 2012-07-30 Sposób przewidywania odpowiedzi na chemioterapię u pacjenta cierpiącego na lub u którego występuje ryzyko wystąpienia nawrotu raka sutka

Country Status (7)

Country Link
US (4) US20140228241A1 (pl)
EP (2) EP2737081B1 (pl)
ES (2) ES2714582T3 (pl)
HU (1) HUE032391T2 (pl)
PL (1) PL2737081T3 (pl)
PT (1) PT2737081T (pl)
WO (1) WO2013014296A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011120984A1 (en) 2010-03-31 2011-10-06 Sividon Diagnostics Gmbh Method for breast cancer recurrence prediction under endocrine treatment
ES2654469T3 (es) 2013-02-01 2018-02-13 Sividon Diagnostics Gmbh Procedimiento de predicción del beneficio de la inclusión de taxano en un régimen de quimioterapia en pacientes con cáncer de mama
JP6164689B2 (ja) * 2013-08-30 2017-07-19 国立大学法人大阪大学 乳癌術前化学療法に対する感受性の診断補助方法および判定装置
PL228355B1 (pl) * 2013-10-15 2018-03-30 Wroclawskie Centrum Badan Eit Spolka Z Ograniczona Odpowiedzialnoscia Sposób wykrywania obnizonej podatnosci na przeciwnowotworowa chemioterapie adjuwantowa cytostatykiem z grupy oksazofosforyn i antybiotykiem z grupy antracyklin u pacjentów z inwazyjnym przewodowym rakiem gruczołu piersiowego (IDC)
EP3105344A1 (en) * 2014-02-12 2016-12-21 Myriad Genetics, Inc. Method for predicting the response and survival from chemotherapy in patients with breast cancer
US11497476B2 (en) * 2015-06-22 2022-11-15 Sunnybrook Research Institute Systems and methods for prediction of tumor treatment response to using texture derivatives computed from quantitative ultrasound parameters
WO2016205936A1 (en) * 2015-06-22 2016-12-29 Sunnybrook Research Institute Systems and methods for prediction of tumor response to chemotherapy using pre-treatment quantitative ultrasound parameters
WO2019051266A2 (en) * 2017-09-08 2019-03-14 Myriad Genetics, Inc. METHOD OF USING BIOMARKERS AND CLINICAL VARIABLES TO PREDICT THE INTEREST OF CHEMOTHERAPY
US20210363594A1 (en) * 2018-09-27 2021-11-25 Biontech Diagnostics Gmbh Predictive and Prognostic Methods in Breast Cancer
US20220162705A1 (en) 2018-11-30 2022-05-26 Gbg Forschungs Gmbh Method for predicting the response to cancer immunotherapy in cancer patients
CN113061655B (zh) * 2021-03-25 2022-04-19 中国科学院合肥物质科学研究院 一组用于预测乳腺癌新辅助化疗敏感性的基因标签及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101356532B (zh) 2005-05-13 2012-08-01 布鲁塞尔自由大学 基于基因的算法型癌症预后
WO2008006517A2 (en) 2006-07-13 2008-01-17 Siemens Healthcare Diagnostics Gmbh Prediction of breast cancer response to taxane-based chemotherapy
US8067178B2 (en) 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
AU2009262894B2 (en) 2008-05-30 2014-01-30 British Columbia Cancer Agency Branch Gene expression profiles to predict breast cancer outcomes
WO2010076322A1 (en) 2008-12-30 2010-07-08 Siemens Healthcare Diagnostics Inc. Prediction of response to taxane/anthracycline-containing chemotherapy in breast cancer
WO2011120984A1 (en) 2010-03-31 2011-10-06 Sividon Diagnostics Gmbh Method for breast cancer recurrence prediction under endocrine treatment

Also Published As

Publication number Publication date
ES2608322T3 (es) 2017-04-07
ES2714582T3 (es) 2019-05-29
EP3150720B1 (en) 2018-12-12
US20170081728A1 (en) 2017-03-23
HUE032391T2 (en) 2017-09-28
WO2013014296A1 (en) 2013-01-31
US20140228241A1 (en) 2014-08-14
EP2737081A1 (en) 2014-06-04
EP3150720A1 (en) 2017-04-05
PT2737081T (pt) 2016-12-23
EP2737081B1 (en) 2016-09-28
US20220307090A1 (en) 2022-09-29
US20190144949A1 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
IL276828A (en) System for accurate 3d modeling of gemstones
EP2888391A4 (en) COMPOSITIONS AND METHODS RELATING TO BLOOD-BASED BIOMARKERS FOR BREAST CANCER
SI2619576T1 (sl) Sredstva in metode za predvidevanje odziva rakavega pacienta na zdravljenje
EP2739153A4 (en) Treatment of breast cancer
IL235795A0 (en) nano46 genes and methods for predicting breast cancer outcome
IL237752B (en) Composition for enhancing specific immunotherapies in cancer treatment
IL252075B (en) Human papilloma virus as predictor of cancer prognosis
EP2891492A4 (en) ENDOPARASITENBEKÄMPFUNGSMITTEL
PL2681333T3 (pl) Ewaluacja odpowiedzi na leczenie endokrynnych nowotworów żołądkowo-trzustkowo-jelitowych (gep-nen)
EP2862082A4 (en) RESTRICTED TRANSACTION
BR112015013444A2 (pt) métodos para caracterizar um câncer
HUE045880T2 (hu) A humán double minute 2 (MDM2) inhibitorra való érzékenységgel összefüggõ markerek
ME03025B (me) Postupci za povećanje efikasnosti terapije kancera usmerene na folr1
PL2714953T3 (pl) Termomechaniczna przeróbka stopów na bazie niklu
PL3287787T3 (pl) Odpowiedź przeciwnowotworowa na zmodyfikowane epitopy własne
HRP20182063T1 (hr) Gen otpornosti na rizomaniju
EP2920308A4 (en) CANCER TREATMENT
SG11201402112RA (en) Use of humanized mice to determine toxicity
GB201212544D0 (en) Device to determine extent of dyskinesia
PT2737081T (pt) Método para prever a resposta a quimioterapia num doente que sofre de ou em risco de desenvolver cancro de mama recorrente
GB2540075B (en) Improvements relating to pipe measurement
HRP20182043T8 (hr) Upotreba anti-koneksinskih sredstava za poboljšanje terapijskog učinka inhibitora acetilkolinesteraze
EP2817011A4 (en) CANCER TREATMENT
EP2997163A4 (en) Methods to predict risk of recurrence in node-positive early breast cancer
HRP20181142T1 (hr) Pripravak za smanjenje apsorpcije masti iz prehrane